Suketu Upadhyay

CIK: 0001533149

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)9 (25.7%)

Derivative conversions

Awards (A)15 (42.9%)

Compensation grants

Other (G, F, J, C, D, …)11 (31.4%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

INCY

INCYTE CORP

Officer

VRTX

VERTEX PHARMACEUTICALS INC / MA

Director

ZBH

ZIMMER BIOMET HOLDINGS, INC.

Officer

Discretionary Trading P&L

Holdings

Transaction History (35 total)

INCY
INCYTE CORP
May 4, 2026
Award(A)
Direct
26.3K shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
May 1, 2026
Award(A)
Deferred Stock Units
Direct
796 shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
May 1, 2026
Award(A)
Stock Option (Right to Buy)
Direct
2.9K shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
May 1, 2026
Disposition(D)
Direct
796 shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
Apr 15, 2026
Award(A)
Deferred Stock Units
Direct
81 shares at avg. $442.50-
ZBH
ZIMMER BIOMET HOLDINGS, INC.
Mar 6, 2026
Tax Payment(F)
Direct
2K shares at avg. $92.54$188K
ZBH
ZIMMER BIOMET HOLDINGS, INC.
Mar 6, 2026
Exercise(M)
Direct
10.2K shares-
ZBH
ZIMMER BIOMET HOLDINGS, INC.
Mar 6, 2026
Tax Payment(F)
Direct
4.5K shares at avg. $92.54$421K
ZBH
ZIMMER BIOMET HOLDINGS, INC.
Mar 6, 2026
Exercise(M)
Direct
4.6K shares-
ZBH
ZIMMER BIOMET HOLDINGS, INC.
Feb 25, 2026
Tax Payment(F)
Direct
2.8K shares at avg. $99.51$282K
ZBH
ZIMMER BIOMET HOLDINGS, INC.
Feb 25, 2026
Exercise(M)
Direct
6.4K shares-
ZBH
ZIMMER BIOMET HOLDINGS, INC.
Feb 20, 2026
Exercise(M)
Direct
5.4K shares-
ZBH
ZIMMER BIOMET HOLDINGS, INC.
Feb 20, 2026
Tax Payment(F)
Direct
2.4K shares at avg. $98.62$241K
ZBH
ZIMMER BIOMET HOLDINGS, INC.
Feb 20, 2026
Award(A)
Restricted Stock Units
Direct
21.7K shares-
ZBH
ZIMMER BIOMET HOLDINGS, INC.
Feb 19, 2026
Award(A)
Restricted Stock Units
Direct
10.2K shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
Jan 15, 2026
Award(A)
Deferred Stock Units
Direct
80 shares at avg. $443.56-
ZBH
ZIMMER BIOMET HOLDINGS, INC.
Nov 10, 2025
Tax Payment(F)
Direct
4.7K shares at avg. $87.73$415K
ZBH
ZIMMER BIOMET HOLDINGS, INC.
Nov 10, 2025
Exercise(M)
Direct
10.6K shares-
ZBH
ZIMMER BIOMET HOLDINGS, INC.
Oct 24, 2025
Award(A)
Restricted Stock Units
Direct
10.6K shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
Oct 15, 2025
Award(A)
Deferred Stock Units
Direct
87 shares at avg. $410.31-
VRTX
VERTEX PHARMACEUTICALS INC / MA
Jul 15, 2025
Award(A)
Deferred Stock Units
Direct
76 shares at avg. $469.34-
VRTX
VERTEX PHARMACEUTICALS INC / MA
May 1, 2025
Award(A)
Direct
796 shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
May 1, 2025
Disposition(D)
Direct
1K shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
Apr 15, 2025
Award(A)
Deferred Stock Units
Direct
72 shares at avg. $497.51-
ZBH
ZIMMER BIOMET HOLDINGS, INC.
Mar 6, 2025
Tax Payment(F)
Direct
2K shares at avg. $104.86$213K

		Type	Shares	Price		Ownership
May 4, 2026	INCY INCYTE CORP	Award(A)	26,343	-	$0	Direct
May 1, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A) Deferred Stock Units	796	-	-	Direct
May 1, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A) Stock Option (Right to Buy)	2,866	-	-	Direct
May 1, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Disposition(D)	796	-	$0	Direct
Apr 15, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A) Deferred Stock Units	81	$442.50	-	Direct
Mar 6, 2026	ZBH ZIMMER BIOMET HOLDINGS, INC.	Tax Payment(F)	2,029	$92.54	$187,764	Direct
Mar 6, 2026	ZBH ZIMMER BIOMET HOLDINGS, INC.	Exercise(M)	10,217	-	$0	Direct
Mar 6, 2026	ZBH ZIMMER BIOMET HOLDINGS, INC.	Tax Payment(F)	4,547	$92.54	$420,779	Direct
Mar 6, 2026	ZBH ZIMMER BIOMET HOLDINGS, INC.	Exercise(M)	4,559	-	$0	Direct
Feb 25, 2026	ZBH ZIMMER BIOMET HOLDINGS, INC.	Tax Payment(F)	2,832	$99.51	$281,812	Direct
Feb 25, 2026	ZBH ZIMMER BIOMET HOLDINGS, INC.	Exercise(M)	6,364	-	$0	Direct
Feb 20, 2026	ZBH ZIMMER BIOMET HOLDINGS, INC.	Exercise(M)	5,445	-	$0	Direct
Feb 20, 2026	ZBH ZIMMER BIOMET HOLDINGS, INC.	Tax Payment(F)	2,446	$98.62	$241,225	Direct
Feb 20, 2026	ZBH ZIMMER BIOMET HOLDINGS, INC.	Award(A) Restricted Stock Units	21,701	-	-	Direct
Feb 19, 2026	ZBH ZIMMER BIOMET HOLDINGS, INC.	Award(A) Restricted Stock Units	10,217	-	-	Direct
Jan 15, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A) Deferred Stock Units	80	$443.56	-	Direct
Nov 10, 2025	ZBH ZIMMER BIOMET HOLDINGS, INC.	Tax Payment(F)	4,731	$87.73	$415,051	Direct
Nov 10, 2025	ZBH ZIMMER BIOMET HOLDINGS, INC.	Exercise(M)	10,632	-	-	Direct
Oct 24, 2025	ZBH ZIMMER BIOMET HOLDINGS, INC.	Award(A) Restricted Stock Units	10,632	-	-	Direct
Oct 15, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A) Deferred Stock Units	87	$410.31	-	Direct
Jul 15, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A) Deferred Stock Units	76	$469.34	-	Direct
May 1, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A)	796	-	-	Direct
May 1, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Disposition(D)	1,001	-	-	Direct
Apr 15, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A) Deferred Stock Units	72	$497.51	-	Direct
Mar 6, 2025	ZBH ZIMMER BIOMET HOLDINGS, INC.	Tax Payment(F)	2,029	$104.86	$212,761	Direct

1-25 of 35 transactions

About Upadhyay Suketu

Upadhyay Suketu (SEC CIK 0001533149) files insider reports with the SEC as EVP & Chief Financial Officer of INCYTE CORP (INCY), Director of VERTEX PHARMACEUTICALS INC / MA (VRTX) and Exec VP, CFO of ZIMMER BIOMET HOLDINGS, INC. (ZBH).

Signal8 holds 20 ownership filings by Upadhyay Suketu (1 Form 3, 19 Form 4), filed between Nov 12, 2024 and May 6, 2026. Those filings report 35 transactions, from Nov 8, 2024 to May 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Upadhyay Suketu's filings is in BOSTON, MA.

Recent filings by Upadhyay Suketu

May 4, 2026: Grant or award of INCY shares (Form 4, code A).
May 1, 2026: Grants or awards of VRTX derivative securities (2 lines, Form 4, code A).
May 1, 2026: Disposition to issuer transaction of VRTX shares (Form 4, code D).
Apr 15, 2026: Grant or award of VRTX derivative securities (Form 4, code A).
Mar 6, 2026: Tax withholding of ZBH shares (Form 4, code F).

Other insiders filing for INCYTE CORP (INCY)

CAGNONI PABLO J, President, Global Head of R&D
Heeson Lee, EVP, Head of Incyte Intl
BAKER BROS. ADVISORS LP, Director
Clancy Paul J, Director
HARRIGAN EDMUND, Director
Gardner David H, EVP, Chief Strategy Officer

How to read Form 4 transaction codes